drug
imlunestrant tosylate
Marketedupdated 5mo agoby Eli Lilly and Co
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4Small molecule drug with a maximum clinical stage of Unknown, with 1 investigational indication.
all catalysts(1)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 25, 2030
~4.0 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Jul 11, 2039compositionUS 10654866
- Jul 11, 2039compositionUS 11117902
FDA exclusivities (1)
- Sep 25, 2030NCENew Chemical Entity (5y)4.0y
News(4)
- An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slideAlkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.biopharma_dive · 7d ago
- FDA approves Lilly's oral SERD combo for second-line breast cancer therapyThe FDA approved a new combination regimen from Eli Lilly for certain breast cancer patients, one that includes Lilly’s oral selective estrogen receptor degrader (SERD) drug Inluriyo. Patients with…endpoints · 10d ago
- FDA approves AstraZeneca’s Etcamah, opening ctDNA-guided treatment paradigm in breast cancerIn a rare divergence from its own expert panel, the FDA has granted accelerated approval to AstraZeneca’s camizestrant, turning a contentious regulatory review into a landmark win that opens a new…fiercebiotech · 21d ago
- Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drugA deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.biopharma_dive · 4mo ago
Data sources
last refreshed 53m ago
Found something off?
comments(0)
5-min edit window · permanent after that